InSilico Medicine Achieves Major Milestone: Inclusion in China Securities Index (CSI) Series
Key Points for Investors
- Inclusion in Multiple CSI Indexes: InSilico Medicine Cayman TopCo (“InSilico Medicine” or the “Company”) has been included in several prestigious China Securities Index (CSI) Series:
- CSI Hong Kong Connect Innovative Drug Index (931250)
- CSI Hong Kong Brand Name Drug Index (931787)
- CSI HK Connect Health Care Composite Index (930965)
The inclusion became effective on June 15, 2026.
- Broader Market Recognition: Prior to this, InSilico Medicine has already achieved inclusion in several other major index series, including:
- Hang Seng Composite Index
- Hang Seng Healthcare Index
- Hang Seng Biotechnology Index
- FTSE Global Small Cap Index
- FTSE Global All Cap Index
- FTSE Global Total Cap Index
- Potential Share Price Sensitivity:
- The inclusion in major CSI indexes is a significant recognition of the Company’s steady fundamentals, technological capabilities, and development potential.
- It is expected to boost InSilico Medicine’s visibility among international institutional investors and research analysts.
- There is potential for capital inflows from passive funds tracking these indexes, which may enhance trading liquidity and diversify the shareholder base.
Implications for Shareholders
- Increased Trading Liquidity: As the Company is included in more indexes, especially those tracked by passive and institutional funds, share trading volumes may increase, potentially leading to improved liquidity and price discovery.
- Broader Institutional Attention: The exposure to a wider base of investors and analysts can attract further investment, possibly affecting future share prices positively.
- Market Confidence: The Board interprets these inclusions as a vote of confidence from the market regarding the Company’s business fundamentals and growth prospects.
Forward-Looking Statement and Advisory
While the Board is optimistic about the potential impacts of these inclusions, investors should note that forward-looking statements regarding the Company’s business development are subject to risks and uncertainties. The financial and other data disclosed have not been audited or reviewed by the Company’s auditors. Shareholders and potential investors are advised to exercise caution in dealing with the Company’s shares and not to place excessive reliance on this announcement. Those in doubt should seek advice from professional advisors.
Company Leadership
The announcement was authorized by the Board, chaired by Mr. Aleksandrs Zavoronkovs, Ph.D. The Board comprises a mix of executive, non-executive, and independent non-executive directors, ensuring diverse oversight and governance.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors are reminded that forward-looking statements are subject to uncertainties and risks, and the Company’s financial data have not been audited. Please consult professional advisers before making investment decisions.
